Roche Holding AG

Equities

ROG

CH0012032048

Pharmaceuticals

Market Closed - Swiss Exchange 11:30:41 2024-05-31 EDT 5-day change 1st Jan Change
231 CHF +1.18% Intraday chart for Roche Holding AG -0.47% -5.52%
LockThis article is reserved for members
To unlock the article, REGISTER!
Already a customer? Log In
ROCHE HOLDINGS AG : Gets a Neutral rating from UBS ZD
Transcript : Roche Holding AG - Shareholder/Analyst Call
ROCHE HOLDINGS AG : Goldman Sachs remains a Sell rating ZD
Swiss Stocks Fall as Rate Jitters Intensify Amid Latest Inflation Data MT
Global markets live: BHP, Anglo American, Lenovo, Nvidia, Apple... Our Logo
European Midday Briefing : Mood Sours as Fed Rate-Cut Bets Curtailed DJ
Roche: FDA grants priority review in breast cancer CF
Roche's Metastatic Breast Cancer Treatment Granted Priority Review by US FDA MT
Roche Breast-Cancer Drug Gets Priority Review in the U.S. DJ
Roche Holding AG Announces U.S. Food and Drug Administration Accepted the New Drug Application and Granted Priority Review to Inavolisib, an Investigational, Oral Therapy, in Combination with Palbociclib (Ibrance®) and Fulvestrant CI
Roche renews diagnostic partnership with Hitachi CF
Roche appoints Director of Corporate Business Development CF
Roche and Hitachi High-Tech Extend Their 46-Year Partnership, Paving the Way for Further Breakthroughs in Diagnostic Testing CI
Roche Announces Management and Board Committee Changes CI
Swiss Market Index Slumps as Economic Data Triggers Rate Jitters Anew MT
ROCHE HOLDINGS AG : Gets a Neutral rating from Deutsche Bank ZD
UK Watchdog Launches Probe into Roche's LumiraDx Purchase MT
Roche, LumiraDx Deal Probed by U.K. Competition Watchdog DJ
Transcript : Roche Holding AG - Analyst/Investor Day
Roche: FDA designation for blood test CF
Roche Gets US FDA Breakthrough Designation For Lipoprotein(a) Test MT
Roche Receives FDA Device Designation for Blood Test Measuring Lp(a) CI
Europe stock pickers go old-school to ride the next wave in AI RE
Global markets live: Microsoft, Roche, BMW, Nintendo, Nordson... Our Logo
Roche: Breakthrough designation for inavolisib in breast cancer CF
Chart Roche Holding AG
More charts
Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
A+
More Ratings
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
20
Last Close Price
231 CHF
Average target price
277.5 CHF
Spread / Average Target
+20.14%
Consensus
  1. Stock Market
  2. Equities
  3. ROG Stock
  4. News Roche Holding AG
  5. Roche Says Investigational Obesity Drug Reduces Weight in Early-stage Study